Approvals/TGA/KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial.

Approved

STANDARD

KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial.

AstraZeneca Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 12d8b933fc172d36
Product Name: KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial.
Artg Id: 459773
Artg Name: KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial.
Sponsor: AstraZeneca Pty Ltd
Company Detail Path: /organization/astrazeneca-pty-ltd
Artg Date: 2025-05-22
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

12d8b933fc172d36

Type

Standard